Entasis Therapeutics (Exited)

Scroll
Name
Entasis Therapeutics (Exited)
About
Boston, USA
Current Development Stage
Clinical
Company Website
http://www.entasistx.com/

Entasis Therapeutics was developing a portfolio of innovative product candidates to treat serious Gram-negative multi-drug resistant bacterial infections. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), ETX0282CPDP (targeting Enterobacteriaceae infections), and Non-Beta-lactam PBP inhibitors or NBPs (targeting Gram-negative infections). In 2022, Entasis was acquired by Innoviva.